Shariq Shamim, MD
Interventional Cardiology · Bridgeton, MONPI 1356657977
Payments from drug & device makers
Across 214 payments — averaging $84.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$9K
- Medtronic$3K
- Boston Scientific$2K
- Abiomed$1K
- Abbott$617
- Angiodynamics, Inc.$447
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$7,20040%
- Travel & lodging$3,78321%
- Food & beverage$7,17739%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 19 | $8,713 |
| Medtronic(2 entities) | 41 | $2,871 |
| Boston Scientific | 23 | $2,023 |
| Abiomed | 10 | $1,021 |
| Abbott | 15 | $617 |
| Angiodynamics, Inc. | 7 | $447 |
| Philips North America LLC | 6 | $343 |
| Inari Medical, Inc. | 3 | $324 |
| Novartis | 39 | $316 |
| Cardiovascular Systems Inc. | 2 | $145 |
| Biotronik Inc. | 1 | $121 |
| Johnson & Johnson | 1 | $115 |
| Novo Nordisk | 5 | $111 |
| Pfizer | 3 | $109 |
| Biosense Webster, Inc. | 1 | $107 |
| Terumo Medical Corporation | 1 | $95 |
| Bard Peripheral Vascular, Inc. | 5 | $89 |
| Edwards Lifesciences | 1 | $81 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| AstraZeneca | 3 | $51 |
| Esperion Therapeutics, Inc. | 3 | $47 |
| Amgen | 3 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $37 |
| Chiesi USA, Inc. | 3 | $35 |
| Resmed Corp | 1 | $34 |
| Asahi Intecc USA, Inc. | 1 | $32 |
| Boehringer Ingelheim | 2 | $31 |
| Corcept Therapeutics | 1 | $25 |
| Amarin Pharma, Inc. | 1 | $22 |
| Teleflex LLC | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Bayer | 1 | $17 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$8,360
- VersaCross Access Solution$1,399
- COREVALVE EVOLUT R$1,072
- Impella$737
- CoreValve Evolut$616
- AngioVac$293
- FLOWTRIEVER CATHETER, S$259
- CT THROMBECTOMY SYSTEM KIT$259
- AMPLATZER AMULET$170
- MitraClip$161
- GENERAL - STENTS$146
- Diamondback Coronary$126
- (4067) Tack Endo Sys BTK$124
- Orsiro Mission$121
- PRO-Kinetic Energy$121
- Passeo-18$121
- PK Papyrus$121
- XARELTO$115
- NUVISION ICE CATHETER$107
- IGT Devices Und$105
How this compares
$18,172 in reported general payments places this provider in the 60th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 53 | $53,275 |
| EliquisApixaban | 41 | $46,937 |
| FarxigaDapagliflozin Propanediol | 43 | $41,170 |
| XareltoRivaroxaban | 14 | $17,939 |
| BrilintaTicagrelor | 18 | $13,929 |
| Dofetilide | 13 | $2,572 |
| Ranolazine ErRanolazine | 18 | $2,210 |
| ClopidogrelClopidogrel Bisulfate | 176 | $1,891 |
| Amiodarone Hcl | 13 | $1,534 |
| Ezetimibe | 48 | $1,422 |
| Rosuvastatin Calcium | 73 | $1,065 |
| Metoprolol Succinate | 77 | $782 |
| Losartan Potassium | 115 | $671 |
| Spironolactone | 78 | $568 |
| Torsemide | 53 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $51 | $55,09961 claims |
| NovartisEntresto | $316 | $53,27553 claims |
| PfizerEliquis | $109 | $46,93741 claims |
| Johnson & JohnsonXarelto | $115 | $17,93914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Bridgeton
- Sundeep DasBridgeton$49K
- Harvey SerotaSaint Louis$7.1M
- Adnan ChhatriwallaKansas City$3.6M
- Gil VardiSaint Louis$2M
- Alan ZajariasSaint Louis$1.6M
- James GranthamKansas City$1.6M
- Anish ThomasSaint Louis$1.5M
- Richard BachSaint Louis$1.5M
- Joshua StolkerWashington$1.2M
- John LasalaSaint Louis$995K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.